Overview

Abilify Therapy for Reducing Comorbid Substance Abuse

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Creighton University
Collaborator:
Bristol-Myers Squibb
Treatments:
Aripiprazole
Criteria
Inclusion Criteria:

1. Ages 19 - 65

2. Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, major
depressive disorder, or anxiety (panic disorder, generalized anxiety disorder, or
post-traumatic stress disorder) as confirmed by Mini International Neuropsychiatric
Interview (MINI) structured assessment

3. Diagnosis of comorbid substance abuse/dependence as confirmed by the MINI structured
assessment

4. Ability to provide signed informed consent

5. Stable general medical health

6. Ability to attend outpatient research clinic.

Exclusion Criteria:

1. Dangerous to self or others

2. Pregnancy, or inability or unwillingness to use approved methods of birth control

3. Inability or unwillingness to provide signed informed consent

4. Inability to attend outpatient research clinic

5. Medical conditions, which would preclude use of aripiprazole

6. Absolute need for ongoing treatment with antipsychotic other than aripiprazole

7. Medical instability defined as likelihood of needing to change prescription medication
during the course of the study

8. Patients with prior unsuccessful treatment with aripiprazole

9. Patients with a psychiatric diagnosis of only antisocial personality disorder or only
an eating disorder and comorbid substance abuse/dependence.